Correlation Between Tempest Therapeutics and Molecular Partners
Can any of the company-specific risk be diversified away by investing in both Tempest Therapeutics and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tempest Therapeutics and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Tempest Therapeutics and Molecular Partners AG, you can compare the effects of market volatilities on Tempest Therapeutics and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tempest Therapeutics with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tempest Therapeutics and Molecular Partners.
Diversification Opportunities for Tempest Therapeutics and Molecular Partners
-0.19 | Correlation Coefficient |
Good diversification
The 3 months correlation between Tempest and Molecular is -0.19. Overlapping area represents the amount of risk that can be diversified away by holding Tempest Therapeutics and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Tempest Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tempest Therapeutics are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Tempest Therapeutics i.e., Tempest Therapeutics and Molecular Partners go up and down completely randomly.
Pair Corralation between Tempest Therapeutics and Molecular Partners
Given the investment horizon of 90 days Tempest Therapeutics is expected to under-perform the Molecular Partners. But the stock apears to be less risky and, when comparing its historical volatility, Tempest Therapeutics is 1.31 times less risky than Molecular Partners. The stock trades about -0.12 of its potential returns per unit of risk. The Molecular Partners AG is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest 567.00 in Molecular Partners AG on August 24, 2024 and sell it today you would lose (25.00) from holding Molecular Partners AG or give up 4.41% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Tempest Therapeutics vs. Molecular Partners AG
Performance |
| Timeline |
| Tempest Therapeutics |
| Molecular Partners |
Tempest Therapeutics and Molecular Partners Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Tempest Therapeutics and Molecular Partners
The main advantage of trading using opposite Tempest Therapeutics and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tempest Therapeutics position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.| Tempest Therapeutics vs. Lyra Therapeutics | Tempest Therapeutics vs. Hookipa Pharma | Tempest Therapeutics vs. Cingulate Warrants | Tempest Therapeutics vs. SAB Biotherapeutics |
| Molecular Partners vs. Mineralys Therapeutics, Common | Molecular Partners vs. AN2 Therapeutics | Molecular Partners vs. Pharvaris BV | Molecular Partners vs. PepGen |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Complementary Tools
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |